

AMENDMENTS TO THE CLAIMS

The following represents a complete listing of the claims in this application indicating the present status of each, including any amendments sought to be entered at this time. Any claims that have been canceled or withdrawn have been canceled or withdrawn without prejudice or disclaimer of any subject matter therein. The applicants specifically reserve the right to pursue any and all such claims in continuing and/or divisional applications. In this paper, claims 35 and 40-41 have been canceled and claims 34, 36, 43, 46, 49 and 50 have been amended.

Listing of the claims:

1-18(canceled).

19(previously presented). A system as in claim 49 wherein said anti-abuse layer contains a binding agent that prevents extraction of said abusable substance of interest using a solvent selected from the group consisting of water, ethanol or combinations thereof.

20(previously presented)). A system as in claim 49 wherein said anti-abuse substance includes activated carbon.

21(previously presented). A system as in claim 19 wherein said anti-abuse substance includes activated carbon.

22(previously presented). A system as in claim 19 wherein said anti-abuse substance includes an amount of an irritant.

23(previously presented). A system as in claim 21 wherein said anti-abuse substance includes an antagonist.

24-33(canceled).

34(currently amended). A disposal system for a skin-worn transdermal patch device containing residual amounts of an abusable substance after use thereof on a patient, said system comprising:

- (a) a container separate from and independent of said skin-worn patch device and having an opening therein for receiving a skin-worn patch device containing a residual amount of an abusable substance therein;
- (b) an amount of an anti-abuse substance including an amount of ~~an active agent~~ activated carbon in said container for treating said abusable substance in said patch device on contact, wherein said anti-abuse substance ~~prevents including material selected from the group consisting of binding and adsorption agents that prevent~~ later independent extraction of said abusable substance of interest using a solvent selected from the group consisting of water, ethanol or combinations thereof, ~~such that~~ and wherein insertion of said skin-worn patch device properly oriented into said container will cause said abusable substance in said skin-worn patch device to contact said anti-abuse substance; and

(c) closure device for closing said disposable container
thereby capturing said skin-worn patch device.

35(canceled).

36(currently amended). A system as in claim ~~35~~ 34 wherein
said anti-abuse substance ~~contains a major fraction of~~ is
substantially activated carbon.

37(previously presented). A system as in claim 34
wherein said container is in the form of a flexible pouch.

38(previously presented). A system as in claim 34
wherein said closure device includes an adhesive seal.

39(previously presented). A system as in claim 37
wherein said closure device includes an adhesive seal.

40-41(canceled)

42(previously presented). A system as in claim 34
wherein a portion of said anti-abuse substance contains an amount
of an agent selected from antagonists, irritants and mixtures
thereof.

43(currently amended). A system as in claim ~~35~~ 36 wherein
a portion of said anti-abuse substance contains an amount of an
agent selected from antagonists, irritants and mixtures thereof.

44(previously presented). A device as in claim 34
wherein said abusable substance is an opioid and said anti-abuse
substance is substantially activated carbon.

45(previously presented). A system as in claim 44
wherein said opioid includes fentanyl.

46(currently amended). A disposal system for a skin-worn transdermal patch device containing residual amounts of an opioid substance after use thereof on a patient, said system comprising:

- (a) a disposable container separate from and independent of said skin-worn patch device and having an opening therein for receiving a skin-worn patch device containing a residual amount of an opioid analgesic substance therein;
- (b) an amount of an activated carbon anti-abuse substance in said container for treating said residual opioid substance in said patch device on contact, wherein insertion of said skin-worn patch device properly oriented into said container will cause said abusable substance in said skin-worn patch device to contact said anti-abuse substance; and
- (c) closure device for closing said disposable container thereby capturing said skin-worn patch device.

47(previously presented). A system as in claim 46 wherein said opioid includes fentanyl.

48(previously presented). A system as in claim 46 wherein a portion of said anti-abuse substance contains an amount of an agent selected from antagonists, irritants and mixtures thereof.

49(currently amended). A skin-worn transdermal patch device for the administration of an abusable substance to a patient, comprising:

- (a) an anti-abuse layer in said patch device containing an amount of an active anti-abuse substance for treating said abusable substance on contact, said anti-abuse substance being selected from the group consisting of active binding agents for said abusable substance in said patch device, co-soluble antagonists, irritants and combinations thereof disposed in said patch device;
- (b) a source layer containing said abusable substance in said patch device;
- (c) ~~a lightly adhering~~ an impermeable separator membrane situated between said anti-abuse layer and said source layer preventing contact therebetween during normal use of said patch when said patch device is adhered to the skin of a user; and
- (d) an extension device ~~associated with~~ connected to said separator membrane and provided with an aspect that adhesively adheres to the skin of a user when said patch is applied and remains adhered to the skin of said user when the patch is removed in a manner that ~~produces automatic withdrawal of~~ sufficient to withdraw said separator membrane from between said ~~layer~~ containing said anti-abuse layer substance and said

source ~~containing said abusable substance~~ layer upon removal of said patch from the skin of said user thereby allowing the anti-abuse layer to contact the abusable substance ~~source layer~~.

50 (currently amended). A device as in claim 49 wherein said abusable substance is an opioid and said anti-abuse substance ~~contains a major fracture of~~ is substantially activated carbon.

51 (previously presented). A system as in claim 49 wherein a portion of said anti-abuse substance contains an amount of an agent selected from antagonists, irritants and mixtures thereof.